Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Table 2 Effect of the re-immunization on VEGF-specific IgG, IgA and IgM antibodies or VEGF/VEGFR2 blockade

Patient code	IgG antibody titer			IgA antibody titer			IgM antibody titer			VEGF/VEGFR2 blockade (%)
	Pre-vaccination	Re-immunization phase		Pre-vaccination	Re-immunization phase		Pre-vaccination	Re-immunization phase		Pre-vaccination	Re-immunization phase
	Week 0	Sample A	Sample B	Week 0	Sample A	Sample B	Week 0	Sample A	Sample B	Week 0	Sample A	Sample B
CH08	4	36	31	49	70	71	1183	1035	1101	11.2	18.7	11.9
JL12	26	700^*	770^*	49	93	56	298	528	604^*	6.92	7.5	15.2^*
CQ13	4	505^*	582^*	335	286	305	1655	2090	2198^†	10.8	29.4^*	24.5^*
CH19	4	232^*	244^*	49	59	68	1180	1462	1978^†	11.5	16.1	31.5^*,#
CH20	1	374^*	339^*	110	94	62	963	629	675	4.6	12.1^*	16.7^*
CH27	8	207^*	236^*	268	472	319	1947	3422	3732^†	14.2	31.1^*	29.9^*
JL29	118	589^*	795^*,†	87	124	144	707	438	557^†	11.2	7.2	20.8^#
JL30	1	17	17	69	72	75	886	663	688	14	19	18
CH33	133	1655^*	1697^*	111	676^*	530^*	2591	341140^*	3859811^*,†	8.7	27.2^*	28.9^*
JL42	41	40	56	70	73	96	1788	1374	2426^†	20	17	27^#
CH45	0	4474^*	3825^*	48	80	84	543	4108^*	4995^*,†	7.6	27.4^*	23^*
JL49	463	947^*	1110^*,†	70	155^*	125	509	1114^*	1027^*	16.3	27.5	34.1^*

Sample “A”: is the value for the sample taken just before the re-immunization; Sample “B”: is the value for the sample acquired 7–10 days after the taking of the sample “A”. [*]: sample meets the positivity criteria for specific-IgG (using formulas A and B), IgA or IgM antibodies (using formula A) or VEGF/VEGFR2 blockade (using formula D). (†): sample meets the criterion of increase for antibody titer: sample “B” - sample “A” ≥ 1/100. (#): sample meets the criterion of increase for VEGF/VEGFR2 blockade: sample “B” - sample “A” ≥ 10%. Patients: CH08 (sample A taken at week 55; sample B taken at week 56); JL12 (sample A taken at week 53; sample B taken at week 54); CQ13 (sample A taken at week 48; sample B taken at week 49); CH19 (sample A taken at week 47; sample B taken at week 48); CH20 (sample A taken at week 50; sample B taken at week 51); CH27 (sample A taken at week 45; sample B taken at week 46); JL29 (sample A taken at week 48; sample B taken at week 49); JL30 (sample A taken at week 52; sample B taken at week 53); CH33 (sample A taken at week 48; sample B taken at week 49); JL42 (sample A taken at week 49; sample B taken at week 50); CH45 (sample A taken at week 48; sample B taken at week 49); JL49 (sample A taken at week 44; sample B taken at week 45)

ISSN: 1471-2172